Dr. Gary L. Buchschacher
Claim this profileKaiser Permanente-Anaheim
Studies Colon Cancer
Studies Colorectal Cancer
14 reported clinical trials
34 drugs studied
Area of expertise
1Colon Cancer
Stage IV
Stage III
BRAF negative
2Colorectal Cancer
Stage III
Stage IV
BRAF negative
Affiliated Hospitals
Clinical Trials Gary L. Buchschacher is currently running
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
Chemotherapy + Bevacizumab + Atezolizumab
for Colorectal Cancer
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Recruiting2 awards Phase 31 criteria
More about Gary L. Buchschacher
Clinical Trial Related7 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Gary L. Buchschacher has experience with
- Fluorouracil
- Irinotecan Hydrochloride
- Leucovorin
- Leucovorin Calcium
- Oxaliplatin
- Paclitaxel
Breakdown of trials Gary L. Buchschacher has run
Colon Cancer
Colorectal Cancer
Prostate Cancer
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gary L. Buchschacher specialize in?
Gary L. Buchschacher focuses on Colon Cancer and Colorectal Cancer. In particular, much of their work with Colon Cancer has involved Stage IV patients, or patients who are Stage III.
Is Gary L. Buchschacher currently recruiting for clinical trials?
Yes, Gary L. Buchschacher is currently recruiting for 6 clinical trials in Anaheim California. If you're interested in participating, you should apply.
Are there any treatments that Gary L. Buchschacher has studied deeply?
Yes, Gary L. Buchschacher has studied treatments such as Fluorouracil, Irinotecan Hydrochloride, Leucovorin.
What is the best way to schedule an appointment with Gary L. Buchschacher?
Apply for one of the trials that Gary L. Buchschacher is conducting.
What is the office address of Gary L. Buchschacher?
The office of Gary L. Buchschacher is located at: Kaiser Permanente-Anaheim, Anaheim, California 92806 United States. This is the address for their practice at the Kaiser Permanente-Anaheim.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.